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Summary
Background Artefenomel (OZ439) is a novel synthetic trioxolane with improved pharmacokinetic properties compared 
with other antimalarial drugs with the artemisinin pharmacophore. Artefenomel has been generally well tolerated in 
volunteers at doses up to 1600 mg and is being developed as a partner drug in an antimalarial combination treatment. 
We investigated the eﬃ  cacy, tolerability, and pharmacokinetics of artefenomel at diﬀ erent doses in patients with 
Plasmodium falciparum or Plasmodium vivax malaria.
Methods This phase 2a exploratory, open-label trial was done at the Hospital for Tropical Diseases, Bangkok, and the 
Shoklo Malaria Research Unit in Thailand. Adult patients with acute, uncomplicated P falciparum or P vivax malaria 
received artefenomel in a single oral dose (200 mg, 400 mg, 800 mg, or 1200 mg). The ﬁ rst cohort received 800 mg. 
Testing of a new dose of artefenomel in a patient cohort was decided on after safety and eﬃ  cacy assessment of the 
preceding cohort. The primary endpoint was the natural log parasite reduction per 24 h. Deﬁ nitive oral treatment was 
given at 36 h. This trial is registered with ClinicalTrials.gov, number NCT01213966.
Findings Between Oct 24, 2010, and May 25, 2012, 82 patients were enrolled (20 in each of the 200 mg, 400 mg, and 
800 mg cohorts, and 21 in the 1200 mg cohort). One patient withdrew consent (before the administration of 
artefenomel) but there were no further dropouts. The parasite reduction rates per 24 h ranged from 0·90 to 1·88 for 
P falciparum, and 2·09 to 2·53 for P vivax. All doses were equally eﬀ ective in both P falciparum and P vivax malaria, 
with median parasite clearance half-lives of 4·1 h (range 1·3–6·7) to 5·6 h (2·0–8·5) for P falciparum and 2·3 h 
(1·2–3·9) to 3·2 h (0·9–15·0) for P vivax. Maximum plasma concentrations, dose-proportional to 800 mg, occurred at 
4 h (median). The estimated elimination half-life was 46–62 h. No serious drug-related adverse eﬀ ects were reported; 
other adverse eﬀ ects were generally mild and reversible, with the highest number in the 1200 mg cohort (17 [81%] 
patients with at least one adverse event). The most frequently reported adverse eﬀ ect was an asymptomatic increase 
in plasma creatine phosphokinase concentration (200 mg, n=5; 400 mg, n=3; 800 mg, n=1; 1200 mg, n=3).
Interpretation Artefenomel is a new synthetic antimalarial peroxide with a good safety proﬁ le that clears parasitaemia 
rapidly in both P falciparum and P vivax malaria. Its long half-life suggests a possible use in a single-dose treatment 
in combination with other drugs.
Funding Bill & Melinda Gates Foundation, Wellcome Trust, and UK Department for International Development.
Copyright © Phyo et al. Open Access article distributed under the terms of CC BY-NC-ND.
Introduction
Malaria is the most important parasitic disease in people, 
and a major cause of morbidity and mortality in tropical 
regions. WHO has declared malaria control a global 
development priority and has changed its focus from 
containment and control to elimination.1 Drug resistance 
in Plasmodium species poses a major obstacle. Resistance 
in Plasmodium falciparum, the main cause of malarial 
death, has rendered several ﬁ rst-line antimalarial drugs 
(ﬁ rst chloroquine, then sulfadoxine-pyrimethamine, and 
in some areas amodiaquine) largely ineﬀ ective. Since 
2005, WHO has recommended artemisinin-based com-
bination therapy as the ﬁ rst-line treatment for falciparum 
malaria.2 Artemisinin and its derivatives are the most 
potent and rapidly acting antimalarial drugs available.3 
The peroxidic pharmacophore is essential for their 
activity.4 The antimalarial activities of artemisinin 
derivatives are characterised by high parasite killing rates 
and broad-stage speciﬁ city of antimalarial action. These 
antimalarial drugs produce more rapid clinical and 
parasitological responses than other classes of available 
drugs.5 However, they are eliminated rapidly (half-lives 
<1 h), which necessitated a treatment course of 7 days 
when they were given alone for falciparum malaria. 
Combination with a more slowly eliminated partner drug 
has allowed for 3-day courses of artemisinin-based 
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combination therapy, improved treatment outcomes, and 
enhanced patient adherence.6,7
WHO recommends that new antimalarial drugs should 
be deployed as combination treatments to provide 
mutual protection against resistance.2,8 Unfortunately, 
artemisinin resistance in P falciparum has emerged, and 
has now spread in southeast Asia, slowing therapeutic 
responses, increasing treatment failure rates, and so 
jeopardising regional control and elimination eﬀ orts.9–11 
This situation emphasises the urgent need for new 
antimalarial drugs if current control and elimination 
initiatives are to be sustained.12
Trioxolanes are synthetic antimalarial drugs with a 
similar peroxide pharmacophore to the artemisinins.13 
The ﬁ rst trioxolane, arterolane (RBx11160/OZ277),14,15 
proved to be well tolerated in people.16–19 Arterolane has 
been developed and registered in India in combination 
with piperaquine and was recently approved in seven 
African countries. The combination has proved highly 
eﬀ ective in a limited number of clinical trials.20 
Artefenomel (OZ439) is the second synthetic trioxolane 
to advance to clinical candidate selection (appendix p 14). 
In a phase 1 study, oral artefenomel (given at doses of 50, 
100, 200, 400, 800, 1200, and 1600 mg) was generally well 
tolerated.21 The good oral bioavailability, slow clearance, 
and increased metabolic stability of artefenomel might 
allow for single-dose cure in combination with a suitable 
partner drug.22 A separate phase 1 study found that 
piperaquine, a potential partner drug, but not 
artefenomel, prolonged the QTc interval in volunteers.23 
We undertook a dose evaluation of artefenomel in acute 
malaria, which assessed parasite clearance rate as a 
measure of antimalarial activity.
Methods
Study design and participants
This phase 2a exploratory, open-label assessment of single-
dose artefenomel in adult patients with acute un-
complicated P falciparum or Plasmodium vivax malaria was 
done at the Hospital for Tropical Diseases, Bangkok, 
Thailand, and the Shoklo Malaria Research Unit (SMRU) 
on the northwestern border of Thailand. Five single oral 
doses of artefenomel were planned over the range 100 mg 
to 1600 mg in cohorts of 20 patients each: two parallel 
groups of ten patients with P falciparum and ten patients 
with P vivax malaria (ﬁ gure 1). Cohort sizes allowed for 
adequate measurement of treatment responses.
Adult male or non-pregnant female febrile patients aged 
18–60 years and weighing 40–90 kg who presented with 
symptomatic malaria (P falciparum or P vivax infections) 
and 5000–50 000 parasites per μL of blood (microscopy 
conﬁ rmed) were eligible, provided that they gave fully 
Research in context
Evidence before this study
Despite progress made during the past few decades, WHO 
reported in 2014 that malaria kills more than half a million 
patients per year (2013 data), and parasite resistance against 
the latest class of antimalarial drugs, the artemisinins, is 
spreading. New antimalarial drugs are needed to drive the 
elimination of malaria.
We searched MEDLINE, the Medicines for Malaria Venture 
website (http://www.mmv.org), the US National Institutes of 
Health and Australian/New Zealand (ANZCTR) trial registries, 
and the Cortellis (Thomson Reuters) database for earlier work 
on artefenomel (OZ439) and similar compounds, with the 
keywords “artefenomel”, “OZ277”, “arterolane”, “Synriam”, 
“ozonides”, “trioxolane”, and “synthetic endoperoxides” to 
search for publications, trial registrations, and other activities 
by mid-July 2015.
Artefenomel is a new, fast-acting inhibitor of all asexual 
erythrocytic Plasmodium falciparum stages associated with 
malaria, and has an in-vitro potency that is similar to clinically 
used artemisinin derivatives. Its intrinsically unstable peroxide 
pharmacophore was optimised, resulting in slower elimination 
compared with artemisinin derivatives and the ﬁ rst-generation 
ozonide arterolane (OZ277). Two phase 1 human volunteer 
studies have shown that oral doses of 50 mg, 100 mg, 200 mg, 
400 mg, 800 mg, 1200 mg, and 1600 mg artefenomel are well 
tolerated, and suggest a good safety proﬁ le for the compound.
Added value of this study
To our knowledge, this study is the ﬁ rst to assess the 
antimalarial activity of artefenomel in patients with malaria. 
Our study assessed the safety and eﬃ  cacy of artefenomel 
before administration of the deﬁ nitive oral antimalarial 
treatment. Our ﬁ ndings show that this synthetic peroxide 
provides rapid parasite clearance in both falciparum and vivax 
malaria. We have established the pharmacokinetic parameters 
that will guide optimum dosing and the choice of appropriate 
partner drugs for antimalarial combination therapy. A 
retrospective genetic analysis of the malaria parasites in this 
study suggests that artefenomel-mediated clearance is not 
substantially aﬀ ected by mutations known to confer partial 
resistance against artemisinins.
Implications of all the available evidence
Our data show that artefenomel has a good pharmacokinetic 
and safety proﬁ le, with antimalarial eﬃ  cacy against both 
P falciparum and Plasmodium vivax, clearing the path for 
further (ongoing) clinical studies. Artefenomel has a longer 
half-life than other antimalarial endoperoxides, with potential 
for a single-dose malaria cure when used with a partner drug. 
Clinical trials in which artefenomel is combined with 
ferroquine (SSR97193), piperaquine, or DSM265 are being 
planned or in progress.
See Online for appendix
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informed written consent. Exclusion criteria were clinical 
or laboratory signs of severe malaria,2 inability to tolerate 
oral drugs, or having received any other antimalarial 
treatment within 14 days before admission.
The protocol, protocol amendments, written study 
patient information, informed consent forms, and other 
appropriate study-related information were reviewed and 
approved by the ethics committee of the Faculty of Tropical 
Medicine, Mahidol University, Bangkok, Thailand. The 
study was done in accordance with Good Clinical Practice 
as required by the International Conference on 
Harmonisation guidelines and in accordance with 
country-speciﬁ c laws and regulations governing clinical 
studies of investigational products. Written, informed 
consent was obtained from all participants.
Procedures
On admission, patients were examined fully, blood 
samples were taken for full blood count and routine 
biochemistry, and the diagnosis of malaria was conﬁ rmed 
by microscopy. The patients were treated with a single oral 
dose of artefenomel after a small full-fat milk drink, 
because food has been reported to aﬀ ect exposure.21 
Patients were monitored closely for the next 36 h. Deﬁ nitive 
oral antimalarial treatment was given at 36 h, or earlier if 
parasitaemia showed no reduction after 12 h, or if the 
reduction after 24 h was lower than 75% (compared with 
baseline). Deﬁ nitive treatment for patients with 
P falciparum malaria was meﬂ oquine 8 mg/kg (base) plus 
4 mg/kg artesunate given once daily for 3 days. Patients 
with P vivax malaria received as deﬁ nitive treatment 25 mg 
base/kg chloroquine; primaquine (0·5 mg base/kg per day 
for 14 days) was given for radical cure of vivax malaria, 
apart from in patients with glucose-6-phosphate 
dehydrogenase (G6PD) deﬁ ciency, who instead received 
0·75 mg primaquine once weekly for 8 weeks.2 Drugs for 
deﬁ nitive treatment were sourced locally by the study sites. 
Patients were considered to have completed the study 
at day 7, but were reviewed again on day 30 (±2 days) to 
ensure cure without complications, and in case any 
adverse event had not resolved.
Patients were recruited sequentially to each dose 
cohort.21 The ﬁ rst cohort received a dose of 800 mg. The 
decision to decrease or increase the dose (within the 
100 mg to 1600 mg range) for sequential cohorts was 
made after a review of the safety data, drug exposure 
levels, and parasite clearance data for the current cohort. 
Parasite genotyping for P falciparum kelch mutations was 
done as described elsewhere.24 G6PD deﬁ ciency was 
assessed with the ﬂ uorescent spot test.25
82 patients enrolled
20 assigned to 800 mg 
artefenomel cohort
21 assigned to 400 mg 
artefenomel cohort
20 assigned to 200 mg 
artefenomel cohort
21 assigned to 1200 mg 
artefenomel cohort
20 received 800 mg 
artefenomel and entered 
into 36 h study period
20 received 400 mg 
artefenomel and entered 
into 36 h study period
20 received 200 mg 
artefenomel and entered 
into 36 h study period
21 received 1200 mg 
artefenomel and entered 
into 36 h study period
20 received definitive 
treatment
20 received definitive 
treatment
20 received definitive 
treatment
21 received definitive 
treatment
20 had follow-up 
examination on day 7
20 had follow-up 
examination on day 7
20 had follow-up 
examination on day 7
21 had follow-up 
examination on day 7
17 had follow-up 
examination on day 30
17 had follow-up 
examination on day 30
18 had follow-up 
examination on day 30
20 had follow-up 
examination on day 30
3 patients withdrew 3 patients withdrew 2 patients withdrew 1 patient withdrew
1 patient withdrew consent 
before artefenomel 
treatment
Figure 1: Study ﬂ ow diagram
A new dose (cohort) was initiated after review of the ﬁ ndings from the preceding cohort. During the 36 h study period, parasitaemia, artefenomel exposure, and 
other variables were assessed. Deﬁ nitive treatment to cure malaria involved standard drugs (meﬂ oquine plus artesunate or chloroquine plus primaquine) and was 
given to avoid recrudescence. Patients infected with Plasmodium falciparum and Plasmodium vivax followed the same clinical protocols. 
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Artefenomel was manufactured by Unimark, India, 
and supplied by Penn Pharmaceuticals in glass vials 
containing 200 mg or 100 mg artefenomel mesylate salt 
stored at 2–8°C. It was administered as aqueous 
dispersion.
Blood samples for the assay of artefenomel and its 
metabolites were obtained before dosing and at 0·5, 1, 2, 
3, 4, 6, 8, 12, 18, 24, 36, 48, 72, 96, and 168 h after dosing. 
An additional blood sample was withdrawn 4 h after 
starting deﬁ nitive antimalarial treatment (ie, typically 
40 h or 76 h after artefenomel administration). Blood 
samples (3 mL) were collected into glass tubes containing 
EDTA (edetic acid) as anticoagulant. Plasma was 
separated within 30 min of sample collection by 
centrifugation at 4°C at 1500 rpm for 15 min, and 
transferred into four polypropylene tubes (three 
replicates of about 500 mL each). The tubes were stored 
frozen at –70°C to –80°C until shipment to the laboratory 
where the analysis was done for the content of 
artefenomel and its metabolites by liquid chroma-
tography–mass spectrometry.21 The limit of quantiﬁ cation 
was 1 ng/mL for all analytes.
Outcomes
The primary endpoint was the natural log parasite 
reduction rate per 24 h. Secondary endpoints were the 
ﬁ rst-order parasite clearance rate constant and derived 
half-life (estimated with the online Worldwide Antimalarial 
Resistance Network [WWARN] toolkit), parasitaemia 
reduction times (50%, 80%, 90%, and 99%), parasite 
clearance time,26–28 gameto cytaemia reduction, and fever 
clearance time. Safety endpoints were incidence, severity, 
drug-relatedness, and seriousness of adverse events and 
of laboratory abnor malities. Additionally, clinically 
signiﬁ cant electro cardiogram (ECG) abnormalities were 
assessed including prolonged QTcF (>450 ms).
The parasite reduction per 24 h was estimated 
separately for each patient from a regression model. The 
relation between parasite counts and time was analysed 
by ﬁ tting a variable lag phase then a linear decline to the 
natural logarithm of parasite count versus time relation. 
The slope of this log-linear relation was the primary 
endpoint, and all secondary variables related to parasite 
reduction were derived from this best ﬁ t. The WWARN 
analytical procedures have been described previously.26
Fever clearance time was deﬁ ned as the time from 
artefenomel administration to the ﬁ rst of at least two 
consecutive normal body temperature measurements (by 
axillary temperature ≤37·5°C or oral, rectal, or tympanic 
temperature ≤38°C) obtained within an interval of 6–24 h 
after artefenomel administration. Incidence of all adverse 
events was scored with the MedRA (latest version) 
primary system organ class and preferred term.29 12-lead 
ECGs were performed on day 0 pre-dose and after dosing, 
2–4 h post-dose, and around 24 h after dosing, and were 
repeated if clinically indicated.
Statistical analysis
Eﬃ  cacy and safety analyses were done by Datamap GmbH 
(Freiburg, Germany) for all patients who received the 
study drug. The primary eﬃ  cacy endpoint (parasite 
reduction rate per 24 h) was derived from linear regression 
ﬁ tting log10-trans formed para sitaemia data against their 
observed times (hours). Only data up to 36 h after dosing 
and before or equal to the start of deﬁ nitive treatment 
were used. The timepoints chosen for the regression were 
those that yield the highest degree of signiﬁ cance when 
assessing the regression when the number of timepoints 
are greater than or equal to three. Parasite reduction rate 
per 24 h and slope were reported with 95% CIs and 
summarised when the regression ﬁ t had a p value less 
than or equal to 0·01 and a corresponding R² greater than 
or equal 0·85. Graphical displays of the Kaplan-Meier 
estimates for parasite clearance time and fever clearance 
200 mg 
(n=20)
400 mg 
(n=21)
800 mg 
(n=20)
1200 mg 
(n=21)
Total 
(n=82)
Sex (male) 19 (95%) 17 (81%) 18 (90%) 17 (81%) 71 (87%)
Age (years) 26·7 (9·8) 29·1 (9·8) 27·2 (8·4) 29·3 (8·2) 28·1 (9·0)
Height (cm) 161·3 (5·6) 164 (8·5) 162·4 (7·4) 159·8 (6·8) 161·9 (7·2)
Bodyweight (kg) 52·4 (5·3) 53·6 (6·2) 57·1 (10·9) 51 (4·4) 53·5 (7·4)
Body-mass index 
(kg/m²)
20·1 (1·4) 19·9 (2·2) 21·5 (2·9) 20 (1·2) 20·4 (2·1)
Body temperature 
(ºC)
38·1 37·9 37·6 37·6 37·8 (0·2)
Haemoglobin (g/L) 121 (15) 125 (17) 123 (14) 170 (13) 124 (89–151)
P falciparum parasites 
per μL (range)
15 425 16 868 42 857 20 914 24 016 
(384–243 270)
P vivax parasites 
per μL (range)
17 369 15 455 20 675 10 118 15 905 
(5010–53 400)
Data are n (%) or geometric means (SD or range). See appendix (pp 3–5) for characteristics of individual patients. All 
patients were of Asian origin.
Table 1: Baseline characteristics
For WWARN analytical 
procedures see http://www.
wwarn.org
Parasite 
reduction rate 
per 24 h
Clearance rate 
(per h)
Slope half-life (h) Duration of lag 
phase (h); number 
of proﬁ les with lag
Number of 
valid 
proﬁ les
P falciparum
200 mg 0·90 (1·7) 0·16 (0·08–0·20) 4·24 (3·50–8·70) 6·0 (4·0–8·40); 4 6
400 mg 1·88 (0·6) 0·13 (0·08–0·35) 5·27 (1·99–9·20) 4·0 (3·90–4·0); 5 10
800 mg 1·55 (0·7) 0·17 (0·10–0·54) 4·05 (1·29–6·70) 6·0 (4·0–8·0); 2 7
1200 mg 1·85 (0·8) 0·12 (0·08–0·34) 5·59 (2·02–8·49) 6·0 (4·0–8·0); 2 11
P vivax
200 mg 2·09 (0·4) 0·22 (0·05–0·81) 3·22 (0·86–15·0) 4·0 (4·0–8·0); 5 10
400 mg 2·20 (0·9) 0·24 (0·10–0·35) 3·10 (2·00–7·23) 8·0 (4·0–8·0); 3 10
800 mg 2·53 (0·7) 0·24 (0·17–0·34) 2·92 (2·01–4·15) 4·0 (4·0–4·0); 1 10
1200 mg 2·22 (0·5) 0·30 (0·18–0·56) 2·34 (1·24–3·88) 4·0 (4·0–4·0); 3 7
Clearance parameters, expressed as median (range), were obtained with the online WWARN Parasite Clearance 
Estimator calculator26 using default settings (40 parasites per μL detection cutoﬀ ). Parasite clearance proﬁ les were 
scored as valid from criteria used by the online WWARN calculator that allow meaningful parameter estimations.26 The 
24 h parasite reduction rates (SD) were calculated separately (see Methods).  
Table 2: Parasite reduction rate per 24 h and parasite clearance, by parasite and artefenomel dose cohort
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time by treatment group were provided. The relation 
between artefenomel exposure (area under the plasma 
concentration-time curve [AUC]0–36) and selected eﬃ  cacy 
endpoints was explored graphically; for each group the 
endpoint was plotted versus AUC0–36, additionally showing 
a LOESS (local regression) ﬁ t, if feasible. This analysis was 
done for parasite reduction rate per 24 h, the slope, and 
36 h ratio, all with linear and log-linear exposure. The 
WWARN Parasite Clearance Estimator calculator is 
described elsewhere.26
Pharmacokinetic analysis was done by Swiss BioQuant 
AG (Reinach, Switzerland). All pharmacokinetic 
variables (normally and log-normally distributed) were 
summarised by arithmetic and geometric means, 
minimum, median, maximum, SD, and coeﬃ  cient of 
variation of arithmetic and geometric means. A non-
linear power model was used to assess dose 
proportionality based on AUC0–∞ (deﬁ ned as area under 
the concentration-time curve from 0 h to inﬁ nity) and 
Cmax (deﬁ ned as maximum or peak plasma concentration) 
values for artefenomel. AUCs were calculated by the 
linear trapezoidal method.
The assessment of dose proportionality was done with 
SAS/STAT software in a UNIX environment. Mean plots 
were generated with GraphPad Prism version 5.00. 
Individual plasma con cen tration-time proﬁ les and non-
compartmental pharma cokinetic analysis were done 
with Professional WinNonlin version 5.2.1. This trial is 
registered with ClinicalTrials.gov, number NCT01213966.
Role of the funding source
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had ﬁ nal 
responsibility for the decision to submit for publication.
Results
82 patients of Thai, Karen, or Burman origin with acute 
uncomplicated malaria were enrolled sequentially: 20 in 
the 200 mg  and 800 mg cohorts, and 21 in the 400 and 
1200 mg cohorts (ﬁ gure 1). The study took place between 
Oct 24, 2010 (ﬁ rst patient enrolled), and May 25, 2012. 
The ﬁ rst cohort was given a dose of 800 mg. The decisions 
on dose escalation or dose reduction for the subsequent 
cohorts were taken after a review of the parasite 
reduction, adverse event, and clinical laboratory data 
after each dosing cohort. The order that doses were given 
to cohorts was 800 mg, 400 mg, 200 mg, and ﬁ nally 
1200 mg. The proportions of patients with P falciparum 
or P vivax malaria diﬀ ered between the two study sites; 
15% of patients (four of 26) presenting in Bangkok were 
infected with P falciparum compared with 67% of patients 
(37 of 55) at the SMRU site; another SMRU patient 
carried a mixed infection (P falciparum plus P vivax).
One patient (400 mg cohort) withdrew consent and was 
not treated with artefenomel. Thus, there were 
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Figure 2: Parasite counts after treatment start per protocol set
Patients with (A) Plasmodium falciparum and (B) Plasmodium vivax. Blue lines show individual patient curves before 
rescue treatment (one patient in 200 mg cohort). The red line represents the median.
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41 evaluable patients with P falciparum (four in Bangkok 
and 37 in SMRU) and 40 evaluable patients with P vivax 
(22 in Bangkok and 18 in SMRU, plus the one SMRU 
patient with mixed infection). No patients required 
deﬁ nitive antimalarial treatment before the end of the 
36 h study period and all recovered uneventfully. Nine 
patients did not return for the follow-up phase (two in 
the 200 mg, three in the 400 mg, three in the 800 mg, and 
one in the 1200 mg cohort). Six (15%) patients with 
P falciparum and none of the patients with P vivax had 
G6PD deﬁ ciency. Individual baseline characteristics are 
shown in table 1 and in the appendix (pp 3–5).
The 24 h parasite reduction rates are listed in table 2. 
These varied from 0·90 to 1·88 for patients with 
P falciparum, and from 2·09 to 2·53 for those with 
P vivax, with no clear dose eﬀ ect for either.
All patients responded rapidly to treatment with a mean 
fever clearance time of 8–30 h (appendix p 6). All 
investigated doses of artefenomel resulted in similar rates 
of parasite clearance (ﬁ gure 2, table 2). The median 
clearance rate constant for P falciparum ranged from 0·12 
to 0·17 per hour leading to a 98% reduction in parasite 
densities by 36 h (appendix p 6 and p 17). The median 
clearance rate constant for P vivax ranged from 0·22 to 
0·30 per hour leading to a 99·6% reduction in parasite 
densities by 36 h. Estimated median parasite clearance 
half-life estimates ranged from 4·1 h to 5·6 h for 
P falciparum and 2·3 h to 3·2 h for P vivax (table 2). In all 
cohorts, parasites were undetectable in blood smears at 
30–36 h after artefenomel administration in patients with 
P falciparum and after 18–24 h in patients with P vivax.
In mainland southeast Asia, slow rates of P falciparum 
parasite clearance after treatment with artesunate are 
associated with mutations in the kelch propeller 
domain.9,30 The median parasite clearance half-life in 
the 19 patients with P falciparum parasites with 
resistance-associated mutations in the kelch 13 
propeller region (P441L, N458Y, F446I, P527H, G538V, 
C580Y, A675A/V, or P667T) was 5·5 h (SD 1·8) 
compared with 4·4 h (1·8) in patients with parasites 
with no mutations in the propeller region (ﬁ gure 3; 
p=0·34; appendix p 13).
There was substantial variability in gametocytaemia 
over time and between cohorts. The low number of 
patients with P falciparum malaria with gametocytaemia 
precluded accurate estimation of gametocyte clearance 
(appendix p 14). For the patients with P vivax, the median 
proportional reduction in gametocytaemia was 97·9% in 
the 800 mg cohort and 90·4% in the 1200 mg cohort at 
24 h, and 100% in the 1200 mg cohort at 48 h.
Maximum plasma concentrations of artefenomel were 
reached about 4 h after administration (table 3, appendix 
p 15), followed by a multiphasic decline. The Cmax values 
were 339 ng/mL, 732 ng/mL, 1710 ng/mL, and 
1500 ng/mL for the 200 mg, 400 mg, 800 mg, and 1200 mg 
doses, respectively. The estimated geometric mean 
terminal phase t1/2 for the parent compound ranged from 
Wild-type Kelch mutants
Pa
ra
sit
e 
cle
ar
an
ce
 h
al
f-
lif
e 
(h
)
10
8
6
4
2
0
1
3
5
7
9
Figure 3: Parasite clearance and kelch mutations
Clearance times for patients infected with parasites with kelch mutations or 
wild-type. The horizontal line represents the median. 
Cmax (ng/mL) tmax (h) AUC0–t (ng.h/mL) AUC0–∞ (ng.h/mL)* t1/2 (h)*
Artefenomel
200 mg 339 (90) 4·0 (2–8) 2490 (101) 3180 (37) 46·3 (54)
400 mg 732 (31) 3·0 (1–6) 6140 (33) 6450 (34) 62·3 (33)
800 mg 1710 (38) 4·0 (2–18) 19 000 (50) 19 700 (50) 58·0 (34)
1200 mg 1500 (90) 4·1 (0·5–12) 21 700 (105) 25 100 (85) 57·0 (47)
OZ567
200 mg 15·6 (59) 4·0 (2–8) 137 (76) NC NC
400 mg 33·2 (39) 4·0 (2–8) 370 (37) NC NC
800 mg 60·1 (57) 4·0 (2–18) 828 (67) NC NC
1200 mg 69·2 (85) 4·0 (3–12) 1140 (94) NC NC
OZ579
200 mg 30·9 (75) 4·0 (2–8) 306 (96) NC NC
400 mg 63·4 (46) 4·0 (2–8) 813 (44) 915 (19) 43·2 (31)
800 mg 105 (73) 4·0 (2–18) 1720 (72) 2100 (54) 41·1 (46)
1200 mg 122 (83) 4·0 (3–24) 2380 (93) 3300 (56) 40·0 (39)
OZ580
200 mg 37·7 (109) 6·0 (4–8) 452 (133) NC NC
400 mg 72·2 (73) 6·0 (3–8) 1150 (76) NC NC
800 mg 83·0 (138) 4·0 (2–12) 1730 (107) NC NC
1200 mg 97·5 (105) 4·0 (3–12) 2200 (117) NC NC
Data are geometric means (coeﬃ  cient of variation) or for tmax, median (range). Number of patients: 20 patients each in 
the 200 mg, 400 mg, and 800 mg cohorts; 21 patients in the 1200 mg cohort. Patients with no assessment at 36 h 
(n=16) were not taken into account. Cmax=maximum or peak plasma concentration. tmax=timepoint at which the 
maximal plasma concentration is reached. AUC0–t=area under the concentration-time curve from 0 h to the last 
pharmacokinetic sample (96 h). AUC0–∞=area under the concentration-time curve from 0 h to inﬁ nity. t1/2=estimated 
terminal phase half-life. *The number of patients may diﬀ er for the variables AUC0–∞ and t1/2. AUC and half-lives were 
not calculated (NC) when fewer than 70% of patients had valid data.
Table 3: Plasma pharmacokinetic variables of artefenomel (OZ439) and its metabolites OZ567, OZ579, 
and OZ580, by artefenomel dose cohort
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46·3 h to 62·3 h. The plasma concentration-time proﬁ les 
for the artefenomel metabolites21 followed those of the 
parent compound with the highest exposures for OZ580 
and the lowest for OZ567 (table 3). These metabolites are 
not thought to contribute signiﬁ cant antimalarial activity.21 
Exposure to all metabolites was lower than for the parent 
drug. Inter-patient variability was generally high for 
exposures to artefenomel and its metabolites (appendix 
p 15). Exposures to artefenomel were similar between 
patients with P falciparum and P vivax infection and 
between male and female patients, and there were no 
apparent eﬀ ects of bodyweight and age.
All patients recovered uneventfully. No patients 
withdrew because of adverse eﬀ ects (see appendix pp 1–2 
and pp 7–9 for a more detailed safety assessment). Two 
serious adverse eﬀ ects were reported, although neither 
was deemed drug related.
Most of the adverse eﬀ ects reported in this study were 
deemed mild in severity by the investigators and no 
particular pattern was evident. The proportion of patients 
with at least one moderate, drug-related event was similar 
between those with P falciparum (43%, 17 of 40 patients) 
and P vivax mono-infection (33%, 13 of 40 patients). Most 
changes in laboratory ﬁ ndings and adverse eﬀ ects were 
mild, reversible, not dose-related, and compatible with 
acute malaria (appendix pp 7–9). Mild, asymptomatic 
increases in hepatic transaminases (alanine amino-
transferase and aspartate amino transferase) were noted, 
but were not dose dependent and were never accompanied 
by hyperbilirubinaemia. Two patients in the 200 mg 
cohort had a transient alanine amino transferase reading 
of 83 U/L (normal range 7–40 U/L for alanine amino-
transferase and aspartate amino transferase) on days 2 
and 7. The highest concentrations for aspartate amino-
transferase were 82 U/L, 75 U/L, and 71 U/L for diﬀ erent 
patients in the 200 mg (2 h and 48 h) and 400 mg (24 h) 
cohorts, respectively. At least one adverse event was 
reported for 13 (65%) patients in the 200 mg cohort, for 11 
(55%) patients in the 400 mg cohort, for ten (50%) 
patients in the 800 mg cohort, and for 17 (81%) patients in 
the 1200 mg cohort. The highest proportion of patients 
with at least one adverse event and the highest number of 
events were reported in the 1200 mg cohort for both 
P falciparum and P vivax. 12 (15%) patients had an 
asymptomatic rise in plasma creatine phosphokinase 
(maximum rise 4·9-fold), which did not correlate with 
dosing (appendix p 8).
Two patients had electrocardiograph QTcF intervals of 
more than 450 ms (one patient at 2 h and 4 h, and one 
patient at 24 h). The longest value recorded was 506 ms 
(pre-dose 423 ms). Both patients were in the 1200 mg 
cohort. In 18 patients, there were 26 instances of QTcF 
prolongation of more than 30 ms compared with baseline 
and three patients had one instance each of QTcF more 
than 60 ms. There was no signiﬁ cant correlation between 
QTcF prolongation and concentrations of artefenomel or 
any of its metabolites (appendix p 11). There were also 
three instances of reversible right bundle branch block, 
one in a patient with accompanying T-wave changes 
compatible with pericarditis evident at baseline, and 
minor non-speciﬁ c T-wave changes were noted. The 
cardiac changes did not seem to be dose-related (one in 
each of the 400 mg, 800 mg, and 1200 mg cohorts) nor 
were they associated with cardiac-related clinical 
symptoms or adverse events.
Discussion
The synthetic peroxide artefenomel is being developed as 
a potential partner drug in an antimalarial combination 
treatment. The main goal of this ﬁ rst study of antimalarial 
activity in vivo was to assess the eﬃ  cacy of artefenomel 
in clearing parasitaemia in uncomplicated malaria. The 
artemisinin derivatives accelerate ring-form parasite 
clearance providing a readily measurable pharma-
codynamic endpoint for dose-ﬁ nding, and this was 
investigated for artefenomel. Doses as low as 200 mg 
proved eﬀ ective at eliminating ring-stage parasites 
rapidly and providing rapid and reliable resolution of 
symptoms and parasitaemia.2 Artefenomel is structurally 
dissimilar to the artemisinins and is eliminated much 
more slowly, yet it retains their key pharmacodynamic 
advantages.
The elimination half-life of artefenomel in patients with 
malaria ranged from 46 h to 62 h, greatly exceeding that of 
other peroxide antimalarial drugs (arterolane 2–4 h,19 
artesunate 0·8–1·3 h,31 and dihydroartemisinin 0·9–2 h.32,33 
The pharmacokinetic properties of artefenomel in acute 
malaria diﬀ ered substantially from those reported earlier 
in healthy volunteers,21 with higher concentrations of 
parent drug and lower concentrations of metabolites, 
suggesting that acute illness aﬀ ects both distribution and 
metabolic clearance. The fairly slow elimination and good 
tolerability up to single doses of 1200 mg suggest that a 
single-dose combination with one or more other slowly 
eliminated antimalarial drugs might be curative, parti-
cularly against blood-stage vivax malaria. The substantially 
slower elimination of artefenomel would provide much 
longer protection against the emergence of partner drug 
resistance than the protection provided by artemisinin 
derivatives in the artemisinin-based combination therapies 
currently in use.
Artemisinin resistance is regarded as the main threat to 
our attempts to control and eliminate malaria. Artemisinin 
resistance in P falciparum manifests as slow parasite 
clearance, delaying clinical recovery, and increased 
gametocyte carriage. Resistance increases transmissibility 
and contributes to increased failure rates with artemisinin 
combination treatments.9,26,34–38 Artesunate produces 
clearance rates in falciparum malaria of between 0·23 and 
0·39 per hour in sensitive infections and 0·10 per hour in 
resistant infections.9,26 These values correspond to parasite 
clearance half-lives of about 2–3 h and 6 h, respectively. By 
comparison, artefenomel provided median parasite 
clearance rates of 0·12 to 0·17 per hour for P falciparum 
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malaria, corresponding to half-lives of 4·1–5·6 h. Thus, 
artefenomel provides parasite clearance rates that are 
slower than those of artesunate on artemisinin-sensitive 
parasites, and slightly faster than those of artesunate on 
artemisinin-resistant parasites (see appendix p 12 for a full 
comparison).
Despite having a similar pharmacophore, the anti-
malarial activity of artefenomel in infections carrying the 
kelch 13 propeller mutations strongly linked with 
artemisinin resistance was not substantially diﬀ erent to 
its activity in infections that did not have these mutations 
(median parasite clearance half-life 5·5 h vs 4·4 h). This 
ﬁ nding suggests that artefenomel might be less aﬀ ected 
by the mechanisms causing artemisinin resistance and 
so might have an important therapeutic role as 
artemisinin resistance worsens. However, this important 
potential advantage will need to be assessed in larger 
patient cohorts.
In general, artefenomel was well tolerated. This study 
included only 81 patients and was not powered to detect 
risks for wider use of the drug. There were no drug-
related serious adverse eﬀ ects and no signiﬁ cant trends 
in nausea and vomiting. Although, overall, drug 
tolerability was good, higher frequencies of adverse 
events and drug-related adverse events were reported in 
the 1200 mg cohort than at the lower doses. The most 
frequently reported adverse eﬀ ect was an asymptomatic 
increase in plasma creatine phosphokinase con-
centration. The highest increase (4·9-fold) was seen in a 
patient in the 200 mg cohort, and there was no dose-
correlation in the 12 readings of increased creatine 
phosphokinase (appendix p 10). Three instances of 
reversible right bundle branch block were reported, one 
in a patient with accompanying T-wave changes com-
patible with pericarditis evident at baseline. Other minor 
non-speciﬁ c T-wave changes were reported. The observed 
cardiac changes did not seem to be dose-related and were 
not associated with cardiac-related clinical symptoms or 
adverse eﬀ ects. Such changes may be seen in healthy 
individuals,39 as well as in patients with malaria,40 so the 
signiﬁ cance of these ﬁ ndings is unclear. Electro-
cardiograms showed QTcF prolongation com pared with 
baseline, but this ﬁ nding was expected because malaria 
is associated with QTcF shortening,41 and so there is 
predictable lengthening of the QT interval with recovery. 
There was no relation between QTcF prolongation and 
plasma concentrations of either parent compound or 
metabolites (appendix p 11). Taken together with the 
absence of QTc prolongation in preclinical studies in 
dogs, these results suggest that artefenomel does not 
substantially aﬀ ect the QT interval in patients.
Our preliminary ﬁ ndings suggest that artefenomel has 
the potential to become an important new antimalarial 
compound. To prevent or delay the development of parasite 
resistance against newly introduced drugs, it is common 
practice to give antimalarial drugs in combination. 
Potential complementary partner drugs for artefenomel 
are ferroquine (SSR97193),42,43 piperaquine,32,44,45 and 
DSM265.46 More information on eﬃ  cacy and safety will be 
needed from additional phase 2 and phase 3 evaluation of 
artefenomel combination studies.
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